Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous […]

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability.
Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin.
Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system.
The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.

Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous system from the damage that can accumulate over time and contribute to disability progression.

Questions around this news

What is myelin, and why does it matter in multiple sclerosis?
Myelin is a protective covering around nerve fibers in the central nervous system. It helps electrical signals travel efficiently. In multiple sclerosis, damage to this covering can disrupt signaling and contribute to neurological symptoms. Protecting myelin and restoring it after damage are areas of research, alongside treatments that target immune activity.
How is remyelination different from preventing demyelination?
Preventing demyelination means aiming to limit damage to existing myelin. Remyelination means rebuilding myelin after it has been damaged. These are related but distinct goals: a treatment might be designed to protect myelin without necessarily restoring myelin that has already been lost. The release describes Lucid-MS as intended to inhibit demyelination and protect myelin.
How might a phase 2 clinical trial contribute to evaluating a treatment?
A phase 2 clinical trial generally studies a treatment in people who have the condition it is intended to address. Researchers gather evidence about its safety and look for signs of whether it may have an effect, often while examining dose or other study questions. Findings can inform whether and how the treatment proceeds to later research.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS, an oral, first-in-class new chemical entity designed to address demyelination through a fundamentally different therapeutic approach. Rather than primarily suppressing or depleting immune cells, Lucid-MS is being developed to protect myelin and inhibit processes that contribute to…

At a glance

Company: Quantum BioPharma Ltd.
Ticker: NASDAQ: QNTM, CSE: QNTM
Announcement: Regulatory

Key figures

Planned clinical trial phase: phase 2

Products and programs

Lucid-MS

SEC filings

Earlier from Quantum BioPharma Ltd.

Back to News Center